Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 959 versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
NL-OMON50383Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing ABP 959 with Eculizumab (2 arms). Primary endpoint: Control of intravascular hemolysis. Started Jun 2019; status: active, not recruiting.
02
Drugs
eculizumab-aeebeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON50383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50383.